

Conference Moderators



Jeffrey Bishop



Jacob Brown



Mark Kirstein



Robert Straka



Brian VanNess

Special Thanks to our Exhibitors

PHARMACOGENOMICS: Genomic Testing to Individualize Drug Therapy

Organized by Department of Experimental and Clinical Pharmacology College of Pharmacy, University of Minnesota, Minneapolis, MN



William Oetting



R. Stephanie Huang

2018 Conference Planning Committee

Pamela Jacobson, Conference Chair

William Oetting

R. Stephanie Huang

Jeffrey Bishop

Jacob Brown

Mark Kirstein

Robert Straka

Brian VanNess

David Stenehjem

Samuel Callisto

Jay (Ya-Feng) Wen


Zachary Rivers

Summer (Dao) Tran

PhD Student Trainees




Samuel Callisto



Jay (Ya-Feng) Wen



Zachary Rivers



Summer (Dao) Tran

Description Pharmacogenomics (PGx) is the science of how an individual's genetic background impacts response to medications. The field is rapidly emerging as a tool for clinical care. Although the field has existed for over 30 years most clinicians remain unsure how to use PGx information. This one-day conference will provide education on a range of topics including somatic mutations and selection of targeted therapies, variants involved in altered analgesic responses, clinical guidelines, use of PGx in children and minority populations, evidence for cost effectiveness and improved quality of care with PGx guided therapies.

Objectives Following completion of this activity, the learner will be able to:

1. Discuss recent advances and future directions in pharmacogenomics.
2. Define how genomic medicine is used in selecting cancer regimens and targeted agents.
3. Describe pharmacogenomic implementation efforts in the U.S.
4. Describe the challenges in using pharmacogenomic testing in minority populations and children where there is limited data.
5. Assess how pharmacogenomic guided therapy could be applied in your practice setting.
6. Discuss the cost effectiveness and reimbursement for pharmacogenomic testing and the challenges related to assessing cost savings.

#UMNPGx2018

AMGEN

AstraZeneca



Bristol-Myers Squibb

FOUNDATION
MEDICINE

Genentech
A Member of the Roche Group

genesight[®]
Changing lives through genetic insight.

illumina[®]

Incyte

IPSEN
Innovation for patient care

Janssen
PHARMACEUTICAL COMPANIES
of Johnson & Johnson

Jazz Pharmaceuticals[®]

MAYO CLINIC
Mayo Medical Laboratories

NOVARTIS

ONEOME[®]

Pfizer

IPM
PUMA
Institute of Personalized Medicine
PGx University of Minnesota Alliance

SANDOZ
A Novartis
Division

SANOFI GENZYME

teva

UNIVERSITY OF MINNESOTA
College of Pharmacy
DEPARTMENT OF EXPERIMENTAL & CLINICAL PHARMACOLOGY

IPM
PUMA
Institute of Personalized Medicine
PGx University of Minnesota Alliance

PHARMACOGENOMICS
CONFERENCE 2018

June 22, 2018
McNamara Alumni Center
University of Minnesota

PHARMACOGENOMICS:
Genomic Testing
to Individualize
Drug Therapy

UNIVERSITY OF MINNESOTA

College of Pharmacy

DEPARTMENT OF EXPERIMENTAL & CLINICAL PHARMACOLOGY

PHARMACOGENOMICS CONFERENCE 2018

June 22, 2018



Pamala Jacobson



Lynda Welage



Julie A. Johnson



Douglas Yee



David Stenehjelm



Shilpa Gupta



Gillian Bell



Jason Karnes



Kelly Caudle



David Gregornik



Mark Dunnenberger



Diana Brixner

PHARMACOGENOMICS: Genomic Testing to Individualize Drug Therapy

Program

7:00-8:00am

Continental Breakfast

8:00-8:10am

Introduction to the Day Pamala Jacobson, PharmD, FCCP, Conference Chair
Professor and Director of the Institute of Personalized Medicine
College of Pharmacy, University of Minnesota, Minneapolis, MN

8:10-8:15am

Welcome Lynda Welage, PharmD
Professor and Dean, College of Pharmacy, University of Minnesota, Minneapolis, MN

8:15-9:00am

Keynote *Improving clinical outcomes through pharmacogenomics*
Julie A. Johnson, PharmD
Dean and Distinguished Professor, College of Pharmacy
University of Florida, Gainesville, FL

9:00-10:30am

Precision Medicine in Cancer

The last decade has been an exciting era for cancer medicine. Speakers will discuss how genetic markers have transformed the treatment of breast cancer. They will also address how somatic tumor mutation information is powerfully guiding targeted drug therapy selection for patients and showing tumor responses in diseases never thought possible. Immunotherapies have emerged into clinical care nearly overnight and biomarkers predicting response are moving into clinical care.

Moderator: Mark Kirstein, PharmD, Associate Professor, Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN

Speakers:

Precision Medicine in Early Stage Breast Cancer: The I-SPY 2 Experience
Douglas Yee, MD, Director of the Masonic Cancer Center
Professor of Medicine and Pharmacology
Medical Oncologist, University of Minnesota, Minneapolis, MN

Using Genetic Biomarkers for Selection of Targeted Cancer Therapies

David Stenehjelm, PharmD, BCOP
Associate Professor, Department of Pharmacy Practice and Pharmaceutical Sciences
College of Pharmacy, University of Minnesota, Duluth, MN

Immunotherapy in the Precision Medicine Era; Profiling to Predict Responsiveness

Shilpa Gupta, MD, Assistant Professor of Medicine
Division of Hematology, Oncology and Transplantation
Lead, Phase 1 Interdisciplinary Solid Tumor Program
Medical School, University of Minnesota, Minneapolis, MN

10:30-11:00am

Coffee and beverage break, visit our Exhibitor booths

11:00-12:00pm

Emerging Areas in Pharmacogenomics

Amidst the backdrop of a nationwide opioid epidemic, the need for improving pain management medicine has never been greater. Our first speaker will discuss of the role of pharmacogenomics to advance precision medicine in pain management with considerations for research and clinical care. Additionally, our growing understanding of genetic diversity has raised awareness about the importance of conducting discovery and clinical pharmacogenomic studies in diverse populations. Our second speaker will talk about this important area and how to advance the field by appropriately examining data from multiethnic study samples.

Moderator: Jeffrey Bishop, PharmD, FCCP, Associate Professor, Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN

Speakers:

Challenges of studying pharmacogenomics in pain management; navigating the genetic and behavioral determinants of analgesia

Gillian Bell, PharmD, Clinical Pharmacist, Personalized Medicine Program
Fullerton Genetics Center, Mission Health, Asheville, NC

Multiethnic Populations and Precision Medicine:

Managing the lack of genetic data and clinical studies

Jason Karnes, PharmD, PhD, BCPS, Assistant Professor, Pharmacy Practice and Science
University of Arizona, College of Pharmacy, Tucson, AZ

12:00-1:30pm

Lunch and review of conference participant pharmacogenomic test results, visit our Exhibitor booths

Who would have predicted 30 years ago that genetic information would predict response or toxicity to medications? It is well-known that drug failure is high for many classes of agents. PGx research has made progress in addressing this problem and now dozens of companies offer PGx testing for clinical care. Participants will be given the opportunity to obtain personal PGx testing for some of the commonly tested variants. Conference participants will be tested prior to the conference and receive the results at conference check-in. The clinical implications for the most common variants identified in conference participants will be discussed over lunch.

Moderators: Pamala Jacobson, PharmD, Jacob Brown, PharmD and Brian VanNess, PhD

1:30-2:30pm

Translating Pharmacogenomic Research into Evidence Based Medication and Dose Recommendations

Speakers will discuss the process of developing Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines and pharmacogenomic information found in the package insert. CPIC is an international consortium facilitating the use of pharmacogenetic tests for children and adults. The FDA Table of Pharmacogenomic Biomarkers in Drug Labeling also contains drug-gene information for nearly 200 drug-gene pairs. However, for many medications or patient populations no guidelines exist. Our speakers will discuss the guidelines and how to apply PGx when no guideline exists.

Moderator: Jacob Brown, PharmD, Assistant Professor, Dept of Pharmacy Practice and Pharmaceutical Sciences
College of Pharmacy, University of Minnesota, Duluth, MN

Speakers:

Creation of CPIC guidelines and drug labeling information to guide PGx prescribing and how to approach drugs without formal guidelines

Kelly Caudle, PharmD, PhD, BCPS
CPIC Director, St Jude Children's Research Hospital
Department of Pharmaceutical Sciences, Memphis, TN

Applying pharmacogenomic testing to children; overcoming limited pediatric data and adult centered guidelines

David Gregornik, PharmD, BCOP
Pharmacogenomics Program Leader, Childrens Hospitals and Clinics Minnesota, Minneapolis, MN

2:30-3:00pm

Coffee and beverage break. Use this time to visit our Exhibitor booths.

3:00-4:00pm

Implementation of Pharmacogenomics in the Real World Setting

As the evidence supporting the clinical significance of genomic-guided drug therapy grows, the importance of establishing the geno-economic value increases. Studies which explore the cost-effectiveness or cost-utility of implementing pharmacogenomics will become central determinants of the rate and extent of uptake and implementation of pharmacogenomics in the real-world setting. This section of the program will review key issues to be considered when evaluating the feasibility and impact of implementing pharmacogenomic-guided drug therapy.

Moderator: Robert Straka, PharmD, FCCP
Professor and Department Head Experimental and Clinical Pharmacology,
College of Pharmacy, University of Minnesota, Minneapolis, MN

Speakers:

Implementation of Pharmacogenomic Testing and a Clinical Service: The NorthShore Experience

Henry 'Mark' Dunnenberger, PharmD, Director - Pharmacogenomics
NorthShore University HealthSystem, Center for Molecular Medicine, Evanston, IL

Insurance Reimbursement and the Payer Perspective on Pharmacogenomics

Diana Brixner, PhD, RPh, FAMCP, Professor, Department of Pharmacotherapy
Executive Director, Outcomes Research Center
Director of Outcomes, Program in Personalized Health Care
University of Utah, Salt Lake City, UT

4:00-4:30pm

Concluding Remarks

Pamala Jacobson, PharmD, FCCP, Conference Chair

Drawing for Books